Major Depressive Disorder

🩺What is Major Depressive Disorder?

The Patient Health Questionnaire-9 (PHQ-9) is a self-administered diagnostic and severity assessment tool for depression, developed by Dr. Robert L. Spitzer and colleagues in 1999. It is derived from the full Patient Health Questionnaire (PHQ), which itself is the self-report version of the Primary Care Evaluation of Mental Disorders (PRIME-MD) diagnostic instrument. Each of the 9 items corresponds to one of the DSM-5-TR diagnostic criteria for major depressive disorder, making it both a screening and severity monitoring instrument. The PHQ-9 asks patients to rate how often they have been bothered by specific problems over the past two weeks, with responses ranging from "not at all" (0) to "nearly every day" (3). Total scores range from 0 to 27, with higher scores indicating greater depression severity. The PHQ-9 has been validated in over 100 languages and across diverse healthcare settings including primary care, obstetrics and gynecology, oncology, cardiology, and neurology. It demonstrates excellent psychometric properties with a sensitivity of 88% and specificity of 88% for major depression at the standard cutoff of 10. The PHQ-9 also includes item 9 which assesses suicidal ideation, making it a critical safety monitoring tool. The US Preventive Services Task Force (USPSTF) recommends depression screening for all adults aged 18 and older, and the PHQ-9 is the most widely recommended instrument. The National Institute for Health and Care Excellence (NICE) in the UK also recommends PHQ-9 for depression assessment in adults. Beyond screening, the PHQ-9 is used longitudinally to track treatment response, with a 5-point change considered clinically significant. The evidence level for PHQ-9 as a screening tool is Grade A, supported by extensive validation studies across multiple populations and settings.

📊Clinical Assessment & Risk Scoring

Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Major Depressive Disorder:

• PHQ-9 Depression Screening Tool

  The Patient Health Questionnaire-9 (PHQ-9) is a validated 9-item screening tool used to assess the severity of depression and monitor treatment response. It is widely used in primary care and psychiatric settings worldwide.

• GAD-7 Anxiety Screening Tool

  The Generalized Anxiety Disorder-7 (GAD-7) is a validated 7-item screening tool used to assess the severity of generalized anxiety disorder and monitor treatment response. It is widely used in primary care, psychiatric, and research settings.

• Mood Disorder Questionnaire (MDQ)

  The Mood Disorder Questionnaire (MDQ) is a validated 13-item screening tool for bipolar spectrum disorders, including bipolar I, bipolar II, and bipolar NOS. It helps identify individuals who may have experienced manic or hypomanic episodes.

• SAD PERSONS Suicide Risk Score

  The SAD PERSONS scale is a 10-item clinical assessment tool for evaluating suicide risk. It uses a simple mnemonic-based scoring system to stratify patients into low, moderate, and high risk categories to guide clinical decision-making.

• PSQI — Pittsburgh Sleep Quality Index

  The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire that assesses sleep quality and disturbances over a 1-month time interval. It is the most widely used standardized measure of sleep quality in clinical research and practice.

🧬Diagnostic Logic & Scoring Breakdown

The PHQ-9 total score is the sum of responses to all 9 questions. Each question is scored 0 ("not at all"), 1 ("several days"), 2 ("more than half the days"), or 3 ("nearly every day"). The minimum total score is 0 and the maximum is 27. A score of 10 or higher is considered the standard cutoff for a positive screen for major depressive disorder. A 5-point reduction from baseline is considered a clinically meaningful treatment response. Item 9 (thoughts of self-harm) should always be reviewed immediately regardless of total score. The PHQ-9 can also be scored as a continuous measure to track severity over time or using the diagnostic algorithm method where a major depressive episode is considered if 5 or more of the 9 items are scored ≥2 and item 1 or 2 (anhedonia or depressed mood) is among them.

📢Clinical Significance & Implications

The PHQ-9 is one of the most widely validated depression screening instruments in clinical medicine. Its clinical significance stems from several key features. First, its item content directly maps to DSM-5-TR diagnostic criteria for major depressive disorder, providing both dimensional severity assessment and categorical diagnostic information. Second, the PHQ-9 has been validated in over 100 languages and across diverse healthcare settings including primary care (sensitivity 88%, specificity 88% at cutoff ≥10), obstetrics and gynecology for postpartum depression screening, oncology for depression in cancer patients, cardiology for post-MI depression, and neurology for depression in stroke and Parkinson's disease. Third, the PHQ-9 is uniquely valuable for longitudinal monitoring — a 5-point change is considered clinically meaningful, and serial PHQ-9 assessments are used to guide treatment decisions and measure outcomes in both clinical practice and research trials. Fourth, the suicide risk assessment item (item 9) provides critical safety information that no other brief depression screening tool offers. The PHQ-9 is embedded in major clinical guidelines worldwide including the USPSTF, NICE, the American Psychiatric Association (APA), the Canadian Network for Mood and Anxiety Treatments (CANMAT), and the Royal Australian and New Zealand College of Psychiatrists (RANZCP). The WHO includes PHQ-9 in its mhGAP programme for use in low-resource settings. Beyond clinical practice, PHQ-9 is the most commonly used depression outcome measure in clinical trials and is the standard tool for measurement-based care in depression treatment.

💡 Clinical Assessment Scenario Example

A 34-year-old female presents to her primary care physician with complaints of low energy, poor sleep, and loss of interest in activities she previously enjoyed. She reports these symptoms have been present for approximately 6 weeks following a stressful period at work. She denies suicidal ideation but notes feeling "down" most days. Her PHQ-9 responses are as follows: Q1 (little interest): 2 (more than half the days), Q2 (depressed mood): 2 (more than half the days), Q3 (sleep): 3 (nearly every day), Q4 (fatigue): 2 (more than half the days), Q5 (appetite): 1 (several days), Q6 (self-worth): 1 (several days), Q7 (concentration): 2 (more than half the days), Q8 (psychomotor): 0 (not at all), Q9 (suicidal thoughts): 0 (not at all). Total score = 2 + 2 + 3 + 2 + 1 + 1 + 2 + 0 + 0 = 13/27. This score falls in the Moderate depression range. The clinical recommendation includes initiating treatment with either an SSRI antidepressant (e.g., sertraline 50 mg daily) or referral for cognitive behavioral therapy (CBT), with close follow-up scheduled in 2 weeks. The patient should be monitored for response using serial PHQ-9 assessments, with a target of 50% reduction in score or a 5-point decrease as evidence of meaningful clinical improvement.

💊Common Medications & Interventions

The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Major Depressive Disorder:

🔗Related Diseases & Conditions

These conditions are clinically associated with Major Depressive Disorder through shared risk-scoring calculators and assessment tools:

• Persistent Depressive Disorder (Dysthymia)
• Generalized Anxiety Disorder
• Panic Disorder
• Bipolar I Disorder
• Bipolar II Disorder
• Suicidal Ideation
• Insomnia Disorder
• Obstructive Sleep Apnea

⚠️Clinical Assessment Pitfalls

• ❌ Mistake: Using PHQ-9 as a standalone diagnostic tool

  ✅ Correction: PHQ-9 is a screening and severity tool, not a replacement for clinical diagnostic interview. Positive screens require comprehensive clinical evaluation.

• ❌ Mistake: Ignoring item 9 (suicidal thoughts) even with low total score

  ✅ Correction: Any score >0 on item 9 requires immediate suicide risk assessment regardless of total score. Never dismiss suicidal ideation.

• ❌ Mistake: Using PHQ-9 for children and adolescents without age-appropriate interpretation

  ✅ Correction: PHQ-9 is validated for adolescents but the PHQ-A (modified version) is preferred. For children under 12, use child-specific tools like the CDI or RCADS.

• ❌ Mistake: Relying solely on total score without reviewing individual item responses

  ✅ Correction: Always review individual item responses, especially items 1-2 (core criteria) and item 9 (safety). The diagnostic algorithm requires ≥5 items scored ≥2 with item 1 or 2 present.

• ❌ Mistake: Not accounting for medical conditions that mimic depression

  ✅ Correction: Hypothyroidism, vitamin D deficiency, sleep apnea, and certain medications can cause depressive symptoms. Rule out organic causes before diagnosing depression.

• ❌ Mistake: Using GAD-7 as a standalone diagnostic tool

  ✅ Correction: GAD-7 is a screening tool, not a diagnostic instrument. Positive screens require comprehensive clinical evaluation to confirm GAD or identify other anxiety disorders.

• ❌ Mistake: Ignoring somatic symptoms of anxiety

  ✅ Correction: Anxiety often presents with somatic symptoms like palpitations, chest tightness, shortness of breath, and GI distress. These should be evaluated and may require medical workup to rule out organic causes.

• ❌ Mistake: Not screening for comorbid depression

  ✅ Correction: Anxiety and depression frequently co-occur (up to 60% comorbidity). Always administer PHQ-9 alongside GAD-7 for comprehensive mood assessment.

• ❌ Mistake: Applying adult GAD-7 cutoffs to children and adolescents

  ✅ Correction: Modified cutoffs may be needed for pediatric populations. The GAD-7 has been validated in adolescents aged 12-17 with similar psychometric properties.

• ❌ Mistake: Using GAD-7 for short-term anxiety states

  ✅ Correction: GAD-7 assesses symptoms over the past 2 weeks. It is not designed for acute anxiety states or situational anxiety. Use appropriate tools like HAM-A for medication trials or VAS for acute anxiety.

• ❌ Mistake: Using MDQ as a diagnostic tool for bipolar disorder

  ✅ Correction: MDQ is a screening tool only. Positive screens require comprehensive diagnostic evaluation using structured clinical interviews (e.g., SCID-5) and DSM-5-TR criteria.

• ❌ Mistake: Ignoring impaired insight in manic patients

  ✅ Correction: Patients experiencing manic episodes may lack insight into their condition and underreport symptoms on the MDQ. Collateral information from family members is essential for accurate assessment.

• ❌ Mistake: Using MDQ alone without impairment criteria

  ✅ Correction: A positive MDQ screen requires all three components: 7+ symptoms, concurrent occurrence, AND functional impairment. Ignoring the impairment criterion significantly increases false positives.

• ❌ Mistake: Not considering bipolar II or cyclothymia

  ✅ Correction: The MDQ is more sensitive for bipolar I disorder than bipolar II. Patients with bipolar II or cyclothymia may have lower MDQ scores but still require clinical evaluation if clinical suspicion exists.

• ❌ Mistake: Failing to rule out medical causes of manic symptoms

  ✅ Correction: Manic-like symptoms can be caused by medical conditions (hyperthyroidism, Cushing's disease, multiple sclerosis), medications (steroids, stimulants, antidepressants), and substances. Rule out organic causes before diagnosing bipolar disorder.

• ❌ Mistake: Using SAD PERSONS as the sole determinant of disposition decisions

  ✅ Correction: SAD PERSONS should supplement, not replace, clinical judgment. A high score should always prompt thorough assessment, but a low score does not rule out risk.

• ❌ Mistake: Not considering protective factors alongside SAD PERSONS

  ✅ Correction: Assess protective factors (family support, future orientation, treatment engagement) to provide a balanced risk formulation.

• ❌ Mistake: Using PSQI as a diagnostic tool for specific sleep disorders

  ✅ Correction: PSQI is a screening instrument for overall sleep quality, not a diagnostic tool for specific sleep disorders like sleep apnea or insomnia. Positive screens require further diagnostic evaluation with specific tools (e.g., polysomnography for sleep apnea).

• ❌ Mistake: Ignoring individual component scores

  ✅ Correction: The 7 component scores provide clinically useful information. For example, high sleep latency with low sleep efficiency suggests insomnia, while high sleep disturbances with normal latency may suggest sleep apnea or periodic limb movements.

• ❌ Mistake: Using PSQI for shift workers without adjustment

  ✅ Correction: Shift workers may require modified administration or interpretation of the PSQI. Consider the 24-hour sleep pattern rather than nocturnal sleep only.

🚑When to Seek Medical Attention

This reference supports clinical assessment of Major Depressive Disorder; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.

❓Frequently Asked Questions

📚Evidence-Based References